• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Nat Immunol . SARS-CoV-2-derived peptides define heterologous and COVID-19-induced T cell recognition

tetano

Editor, Senior Moderator
Nat Immunol


. 2020 Sep 30.
doi: 10.1038/s41590-020-00808-x. Online ahead of print.
SARS-CoV-2-derived peptides define heterologous and COVID-19-induced T cell recognition


Annika Nelde[SUP] 1 2 3 [/SUP], Tatjana Bilich[SUP] 1 2 3 [/SUP], Jonas S Heitmann[SUP] 1 3 [/SUP], Yacine Maringer[SUP] 1 2 3 [/SUP], Helmut R Salih[SUP] 1 3 4 [/SUP], Malte Roerden[SUP] 2 3 5 [/SUP], Maren L?bke[SUP] 2 [/SUP], Jens Bauer[SUP] 1 2 [/SUP], Jonas Rieth[SUP] 1 2 [/SUP], Marcel Wacker[SUP] 1 2 [/SUP], Andreas Peter[SUP] 6 [/SUP], Sebastian H?rber[SUP] 6 [/SUP], Bjoern Traenkle[SUP] 7 [/SUP], Philipp D Kaiser[SUP] 7 [/SUP], Ulrich Rothbauer[SUP] 7 8 [/SUP], Matthias Becker[SUP] 7 [/SUP], Daniel Junker[SUP] 7 [/SUP], G?rard Krause[SUP] 9 10 11 [/SUP], Monika Strengert[SUP] 9 10 [/SUP], Nicole Schneiderhan-Marra[SUP] 7 [/SUP], Markus F Templin[SUP] 7 [/SUP], Thomas O Joos[SUP] 7 [/SUP], Daniel J Kowalewski[SUP] 12 [/SUP], Vlatka Stos-Zweifel[SUP] 12 [/SUP], Michael Fehr[SUP] 2 [/SUP], Armin Rabsteyn[SUP] 3 13 [/SUP], Valbona Mirakaj[SUP] 14 [/SUP], Julia Karbach[SUP] 15 [/SUP], Elke J?ger[SUP] 15 [/SUP], Michael Graf[SUP] 16 [/SUP], Lena-Christin Gruber[SUP] 1 [/SUP], David Rachfalski[SUP] 1 [/SUP], Beate Preu?[SUP] 5 [/SUP], Ilona Hagelstein[SUP] 1 3 [/SUP], Melanie M?rklin[SUP] 1 3 [/SUP], Tamam Bakchoul[SUP] 17 [/SUP], C?cile Gouttefangeas[SUP] 2 3 4 [/SUP], Oliver Kohlbacher[SUP] 16 18 19 20 [/SUP], Reinhild Klein[SUP] 5 [/SUP], Stefan Stevanović[SUP] 2 4 [/SUP], Hans-Georg Rammensee[SUP] 2 3 4 [/SUP], Juliane S Walz[SUP] 21 22 23 [/SUP]



Affiliations

Abstract

T cell immunity is central for the control of viral infections. To characterize T cell immunity, but also for the development of vaccines, identification of exact viral T cell epitopes is fundamental. Here we identify and characterize multiple dominant and subdominant SARS-CoV-2 HLA class I and HLA-DR peptides as potential T cell epitopes in COVID-19 convalescent and unexposed individuals. SARS-CoV-2-specific peptides enabled detection of post-infectious T cell immunity, even in seronegative convalescent individuals. Cross-reactive SARS-CoV-2 peptides revealed pre-existing T cell responses in 81% of unexposed individuals and validated similarity with common cold coronaviruses, providing a functional basis for heterologous immunity in SARS-CoV-2 infection. Diversity of SARS-CoV-2 T cell responses was associated with mild symptoms of COVID-19, providing evidence that immunity requires recognition of multiple epitopes. Together, the proposed SARS-CoV-2 T cell epitopes enable identification of heterologous and post-infectious T cell immunity and facilitate development of diagnostic, preventive and therapeutic measures for COVID-19.
 
Back
Top Bottom